Research Advances of IDH2 Gene Mutation in Acute Myeloid Leukemia.
10.7534/j.issn.1009-2137.2016.02.061
- Author:
Yan-Xia ZHAO
1
;
Xu-Liang SHEN
2
Author Information
1. Changzhi Medical College, Changzhi 046000, Shanxi Province, China.
2. Department of Hematology, Peace Hospital Affiliated to Changzhi Medical College, Changzhi 046000, Shanxi Province, China. E-mail: shenxlcyp@sohu.com.
- Publication Type:Journal Article
- MeSH:
Humans;
Isocitrate Dehydrogenase;
genetics;
Leukemia, Myeloid, Acute;
genetics;
Mutation;
Neoplasm, Residual;
Prognosis
- From:
Journal of Experimental Hematology
2016;24(2):632-636
- CountryChina
- Language:Chinese
-
Abstract:
Acute myeloid leukemia (AML) is a malignant clonal hematologic disease from hematopoietic stem and progenitor cells. The isocitrate dehychogenase 2 (IDH2) gene mutation has been recently found, which may be associated with the course of AML. The incidence of IDH2 gene mutation in the patients with acute myeloid leukemia is high, especially in the AML patients with normal karyotype. Different subtypes of IDH2 mutation, or companing other molecular biology, will make different influence on clinical features and progress of patients with AML. IDH2 mutation is stable, which can be used as the test sign of AML and minimal residual disease (MRD), and for guiding the clinical treatment and predicting the progress. In this article, the research progress of IDH2 mutation in acute myeloid leukemia is reviewed.
